← All trials
NCT04470778
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 20, 2020
- Primary completion
- Oct 12, 2020
- Completion date
- Oct 13, 2020
- First posted
- Jul 14, 2020
- Last posted
- Aug 24, 2020
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.